Effect of Chronic Treatment with Riluzole on the Nigrostriatal Dopaminergic System in Weaver Mutant Mice

This publication has 41 references indexed in Scilit:

• Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease
  Annals of Neurology, 2001
• The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation
  Neuropharmacology, 2000
• Glial cell line-derived neurotrophic factor protects midbrain dopamine neurons from the lethal action of the weaver gene: a quantitative immunocytochemical study
  Developmental Brain Research, 1999
• Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model
  European Journal of Pharmacology, 1998
• Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area
  Molecular Brain Research, 1996
• Selective vulnerability of late-generated dopaminergic neurons of the substantia nigra in weaver mutant mice.
  Proceedings of the National Academy of Sciences, 1995
• Riluzole and experimental parkinsonism
  NeuroReport, 1994
• Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre
  Pflügers Archiv - European Journal of Physiology, 1991
• 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission—II Biochemical properties
  Neuropharmacology, 1985